Warning Letter Roundup: FDA Slaps Facilities on Data Integrity, Quality

Drug GMP Report
A A
GMP woes for foreign and domestic facilities continued as the FDA issued three warning letters to Indian and Chinese factories as well as a U.S. facility over data integrity and quality control problems.

To View This Article:

Login

Subscribe To Drug GMP Report